Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02725489Phase 2Completed

Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers

Role: lead

NCT00684294Phase 1Terminated

Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer

Role: lead

NCT00125749Phase 1Completed

Vaccination of Patients With Stage IV Melanoma With Dendritic Cells

Role: collaborator

NCT01274572Withdrawn

Blood for Immune Response to Provenge® in HRPC

Role: lead

All 4 trials loaded